Randomised clinical trial: Mesalazine and/or probiotics in maintaining remission of symptomatic uncomplicated diverticular disease - A double-blind, randomised, placebo-controlled study

Alimentary Pharmacology and Therapeutics

Volumn 38, Issue 7, 2013, Pages 741-751

  Tursi, A ^a   Brandimarte, G ^b   Elisei, W ^c   Picchio, M ^d   Forti, G ^e   Pianese, G ^e   Rodino, S ^f   D'Amico, T ^f   Sacca, N ^f   Portincasa, P ^g   Capezzuto, E ^h   Lattanzio, R ⁱ   Spadaccini, A ^j   Fiorella, S ^j   Polimeni, F ^k   Polimeni, N ^k   Stoppino, V ^l   Stoppino, G ^l   Giorgetti, G M ^m   Aiello, F ⁿ   Danese, S ^o   more..

^a ASL BAT   (Italy)

^b Cristo Re Hospital   (Italy)

^c ASL RMH   (Italy)

^d Hospital P Colombo   (Italy)

^e SANTA MARIA GORETTI HOSPITAL   (Italy)

^f PUGLIESE CIACCIO HOSPITAL   (Italy)

^g POLICLINICO   (Italy)

^h GB Grassi Hospital   (Italy)

ⁱ Popoli Hospital   (Italy)

^j Obstetric and Gynaecology Department   (Italy)

^k AO Bianchi Melacrino Morelli   (Italy)

^l Division of Nephrology Dialysis and Transplantation   (Italy)

^m S EUGENIO HOSPITAL   (Italy)

ⁿ KORE UNIVERSITY OF ENNA   (Italy)

^o HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ENTEROLACTIS; MESALAZINE; PENTACOL; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ACUTE DISEASE; ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIVERTICULOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; LACTOBACILLUS CASEI; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; REMISSION; SYMPTOMATIC UNCOMPLICATED DIVERTICULAR DISEASE; TREATMENT DURATION;

ABDOMINAL PAIN; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIVERTICULUM, COLON; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; LACTOBACILLUS; MALE; MESALAMINE; MIDDLE AGED; PROBIOTICS; RECURRENCE; TREATMENT OUTCOME;

EID: 84883475412     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12463     Document Type: Article

References (32)

1. Humes DJ,. Changing epidemiology: does it increase our understanding? Dig Dis 2012; 30: 6-11.
2. Latella G, Pimpo MT, Sottili S, et al,. Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003; 18: 55-62.
3. Humes DJ, Simpson J, Smith J, et al,. Visceral hypersensitivity in symptomatic diverticular disease and the role of neuropeptides and low grade inflammation. Neurogastroenterol Motil 2012; 24: 318-e163.
4. Tursi A, Joseph RE, Streck P,. Expanding applications: the potential usage of 5-aminosalicylic acid in diverticular disease. Dig Dis Sci 2011; 56: 3112-21.
5. Floch MH,. A hypothesis: is diverticulitis a type of inflammatory bowel disease? J Clin Gastroenterol 2006; 40 (Suppl. 3): S121-5.
6. Tursi A,. Antibiotics and probiotics in the treatment of diverticular disease. J Clin Gastroenterol 2011; 45 (Suppl.): S46-52.
7. Tursi A, Brandimarte G, Giorgetti GM, et al,. Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon: a prospective, randomized, open-label study. J Clin Gastroenterol 2006; 40: 312-6.
8. Köhler L, Sauerland S, Neugebauer E,. Diagnosis and treatment of diverticular disease: results of a consensus development conference. The Scientific Committee of the European Association for Endoscopic Surgery. Surg Endosc 1999; 13: 430-6.
9. Spiller RC,. Is it diverticular disease or is it irritable bowel syndrome? Dig Dis 2012; 30: 64-9.
10. Papi C, Ciaco A, Koch M, et al,. Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 1995; 9: 33-9.
11. Charlson ME, Pompei P, Ales KL, et al,. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987; 40: 373-83.
12. Charlson ME, Szatrowski TP, Peterson J, et al,. Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245-51.
13. Moreno AM, Wille-Jørgensen P,. Long-term outcome in 445 patients after diagnosis of diverticular disease. Colorectal Dis 2007; 9: 464-8.
14. Gatta L, Di Mario F, Curlo M, et al,. Long-term treatment with mesalazine in patients with symptomatic uncomplicated diverticular disease. Intern Emerg Med 2012; 7: 133-7.
15. Stollman NH, Raskin JB,. Diagnosis and management of diverticular disease of the colon in adults. Ad Hoc Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 3110-21.
16. Tursi A,. New physiopathological and therapeutic approaches to diverticular disease of the colon. Expert Opin Pharmacother 2007; 8: 299-307.
17. Zullo A, Hassan C, Maconi G, et al,. Cyclic antibiotic therapy for diverticular disease: a critical reappraisal. J Gastrointestin Liver Dis 2010; 19: 295-302.
18. Maconi G, Barbara G, Bosetti C, et al,. Treatment of diverticular disease of the colon and prevention of acute diverticulitis: a systematic review. Dis Colon Rectum 2011; 54: 1-12.
19. Tursi A, Brandimarte G, Elisei W, et al,. Assessment and grading of mucosal inflammation in colonic diverticular disease. J Clin Gastroenterol 2008; 42: 699-703.
20. Tursi A, Brandimarte G, Elisei W, et al,. Faecal calprotectin in colonic diverticular disease: a case-control study. Int J Colorectal Dis 2009; 24: 49-55.
21. Kruis W, Meier E, Schumacher M, et al,.; German SAG-20 Study Group. Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon-a placebo-controlled study. Aliment Pharmacol Ther 2013; 37: 680-90.
22. Gaman A, Teodorescu R, Georhescu EF, et al,. Prophylactic effects of mesalamine in diverticular disease. Falk Symp 178 2011; Abstract 13.
23. Smith J, Humes D, Garsed K, et al,. Mechanistic randomized control trial of mesalazine in symptomatic diverticular disease. Gut 2012; 61 (Suppl. 2): A51-2.
24. Tursi A,. Antibiotics and probiotics in the treatment of diverticular disease. J Clin Gastroenterol 2011; 45 (Suppl. 1): S46-52.
25. Dugas B, Mercenier A, Lenoir-Wijnkoop I, et al,. Immunity and probiotics. Immunol Today 1999; 20: 387-90.
26. Cats A, Kuipers EJ, Bosschaert MAR, et al,. Effect of frequent consumption of a Lactobacillus casei-containing milk drink in Helicobacter pylori-colonized subjects. Aliment Pharmacol Ther 2003; 17: 429-35.
27. Etzioni DA, Chiu VY, Cannom RR, et al,. Outpatient treatment of acute diverticulitis: rates and predictors of failure. Dis Colon Rectum 2010; 53: 861-5.
28. Humes DJ, Fleming KM, Spiller RC, et al,. Concurrent drug use and the risk of perforated colonic diverticular disease: a population-based case-control study. Gut 2011; 60: 219-24.
29. Hall JF, Roberts PL, Ricciardi R, et al,. Long-term follow-up after an initial episode of diverticulitis: what are the predictors of recurrence? Dis Colon Rectum 2011; 54: 283-8.
30. Tursi A, Elisei W, Giorgetti GM, et al,. Detection of endoscopic and histological inflammation after an attack of colonic diverticulitis is associated with higher diverticulitis recurrence. J Gastrointestin Liver Dis 2013; 22: 13-9.
31. Shire. Shire Announces Top-line Results of the PREVENT 2 Trial. Volume 2012, 2012. Available at: http://www.shire.com/shireplc/en/media/shirenews?id= 583.
32. Stollman N, Magowan S, Shanahan F, et al,.; for the DIVA Investigator Group. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial. J Clin Gastroenterol 2013; 47: 621-9.